Last reviewed · How we verify
NCT03717454
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
NA trial testing Surgery in Prolactinoma in 50 participants. Status unknown.
30 December 2021
Quick facts
| Lead sponsor | Zhebao Wu |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 December 2018 |
| Primary completion | 30 December 2021 |
| Estimated completion | 31 January 2022 |
Drugs / interventions tested
- Surgery
- Drug treatment — full drug profile →
Conditions studied
- Prolactinoma — all drugs for Prolactinoma →
Sponsor
Zhebao Wu — full company profile →
Who can join
Adults 18 to 65, any sex, with Prolactinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03717454
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgery
Trials testing the same drug.
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
- NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
- NCT07352007 — Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular · Phase 2 · not yet recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other recruiting trials for Prolactinoma
Currently open trials in the same condition.
- NCT07463235 — Safety and Potency of a High Cabergoline Dosage in Microprolactinomas · Phase 3 · recruiting
- NCT07268183 — How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors · recruiting
- NCT07045935 — Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment · Phase 4 · recruiting
- NCT06936813 — The PROMISE Survey · active not recruiting
- NCT00001595 — An Investigation of Pituitary Tumors and Related Hypothalmic Disorders · recruiting
Other Zhebao Wu trials
Trials by the same sponsor.
- NCT04018963 — The Impact of Endoscopic Pituitary Surgery on Nasal Function · unknown
- NCT03714763 — Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA) · NA · unknown
- NCT03400865 — Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03717454 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhebao Wu
- Last refreshed: 20 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717454.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing